75% of med-tech companies go overseas 1st because of FDA lead times and unpredictability

     Report: More than 75% of med-tech companies go overseas first (MassDevice)

More than three-quarters of medical device makers go overseas first when launching new products, according to researchers at Northwestern University.

High costs, long review times and increasing unpredictability led more than three-quarters of medical device makers to seek overseas regulatory approval before launching a bid for FDA clearance, according to the largest-ever survey on the 510(k) review process. Of 350 medical device company employees reviewed, 22 percent said high costs of FDA review sent them o...


Unlock the full article and exclusive OrthoStreams insights: in-depth analyses, hot startups, trends, market intel, and Daily Newsletter—for just $1/day.
Subscribe Now—Up your Game !
 

Scroll to Top